All In Biotech

Free tool

FAERS Monitor: Pepcid Complete

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020958 or its brand name (Pepcid Complete, Calcium Carbonate, Famotidine, Magnesium Hydroxide). Reports on generic versions are filed under their own applications.

Reports

2,416

Serious

816

34% of reports

Hospitalization

121

Death reported

74

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • chronic kidney disease483
  • drug ineffective312
  • acute kidney injury257
  • renal failure174
  • end stage renal disease133
  • gastrooesophageal reflux disease133
  • off label use100
  • product use in unapproved indication100
  • wrong technique in product usage process98
  • incorrect dose administered97
  • therapeutic response unexpected93
  • product physical issue83
  • dysgeusia78
  • nausea75
  • renal injury74

Reports by year received

View as table
YearReports
20044
20055
20065
20079
200812
200937
201016
201118
201214
20137
201410
2015165
2016150
2017232
2018254
2019334
2020208
2021207
2022143
2023172
2024110
2025170
2026134

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,743 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
end stage renal diseaseSignal13363.954.28,125
chronic kidney diseaseSignal48355.751.425,814
product physical issueSignal8336.029.12,777
renal injurySignal7421.717.41,441
therapeutic response unexpectedSignal9318.114.81,484
acute kidney injurySignal25714.613.03,272
gastrooesophageal reflux diseaseSignal13314.412.21,649
renal failureSignal17411.49.91,652
dysgeusiaSignal789.17.4559
wrong technique in product usage processSignal984.23.5239
incorrect dose administeredSignal973.73.0190
product use in unapproved indicationSignal1003.52.9179
drug ineffectiveSignal3122.11.9181
off label use1001.00.80
nausea750.80.73

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.